AAAAAA
Results:
1-9
|
Results: 9
Authors:
RUCKLE JL
HATORP V
Citation: Jl. Ruckle et V. Hatorp, REPAGLINIDE PHARMACOKINETICS IN PATIENTS WITH RENAL IMPAIRMENT VERSUSHEALTHY-VOLUNTEERS, Diabetologia, 41, 1998, pp. 911-911
Authors:
HATORP V
HAUGPIHALE G
Citation: V. Hatorp et G. Haugpihale, A COMPARISON OF THE PHARMACOKINETICS OF REPAGLINIDE IN HEALTHY-SUBJECTS WITH THAT IN SUBJECTS WITH CHRONIC LIVER-DISEASE, Diabetologia, 41, 1998, pp. 912-912
Authors:
MARBURY TC
HATORP V
DAMSBO P
MULLER PG
Citation: Tc. Marbury et al., REPAGLINIDE CAN BE GIVEN IN A FLEXIBLE PREPRANDIAL DOSING REGIMEN IN PATIENTS WITH TYPE-2 DIABETES, Diabetologia, 41, 1998, pp. 913-913
Authors:
MARBURY TC
HATORP V
DAMSBO P
MULLER PG
Citation: Tc. Marbury et al., REPAGLINIDE CAN BE GIVEN IN A FLEXIBLE PREPRANDIAL DOSING REGIMEN IN PATIENTS WITH TYPE-2 DIABETES, Diabetes, 47, 1998, pp. 1373-1373
Authors:
VANHEININGEN PNM
HATORP V
VANLIER JJ
VANDEMERBEL NC
JONKMAN JHG
Citation: Pnm. Vanheiningen et al., DISPOSITION OF ONE DOSE OF C-14-REPAGLINIDE DURING NON-LABELED REPAGLINIDE MULTIPLE DOSING, Diabetes, 47, 1998, pp. 1374-1374
Authors:
HATORP V
HAUGPIHALE G
Citation: V. Hatorp et G. Haugpihale, A COMPARISON OF THE PHARMACOKINETICS OF REPAGLINIDE IN HEALTHY-SUBJECTS WITH THAT IN SUBJECTS WITH CHRONIC LIVER-DISEASE, Diabetes, 47, 1998, pp. 1375-1375
Authors:
MARBURY TC
HATORP V
Citation: Tc. Marbury et V. Hatorp, PHARMACOKINETICS OF REPAGLINIDE AFTER SINGLE AND MULTIPLE DOSES IN PATIENTS WITH RENAL IMPAIRMENT COMPARED WITH NORMAL HEALTHY-VOLUNTEERS, Diabetes, 47, 1998, pp. 1381-1381
Authors:
OLIVER S
AHMAD S
WINFELD K
HATORP V
Citation: S. Oliver et al., PHARMACOKINETICS AND BIOAVAILABILITY OF REPAGLINIDE, A NEW OHA FOR PATIENTS WITH NIDDM, Diabetologia, 40, 1997, pp. 1260-1260
Authors:
OLIVER S
WINDFELD K
HATORP V
Citation: S. Oliver et al., PHARMACOKINETICS AND BIOAVAILABILITY OF REPAGLINIDE, A NEW OHA FOR PATIENTS WITH NIDDM, Diabetes, 46, 1997, pp. 1263-1263
Risultati:
1-9
|